CFO
LXRX icon

Callan Family Office’s Lexicon Pharmaceuticals LXRX Stock Holding History

Callan Family Office’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Hold
14,090
– – ﹤0.01% 1207
2026
Q1 		$22K Hold
14,090
– – ﹤0.01% 1125
2025
Q4 		$16.2K Buy
+14,090
New +$19.4K ﹤0.01% 1109

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Callan Family Office's LXRX Position: Q2 2026 in Review

Callan Family Office held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 14,090 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1207.

Callan Family Office first reported a position in LXRX in Q4 2025 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Callan Family Office held 14,090 shares of Lexicon Pharmaceuticals worth $33.8K as of Q2 2026.
  • Callan Family Office left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1207 holding.
  • Callan Family Office first reported a position in Lexicon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.